nach oben

Clinical and Translational Oncology

Erschienen in:

01.02.2016 | Review Article

Twist as a new prognostic marker in hematological malignancies

verfasst von: F. Norozi, A. Ahmadzadeh, M. Shahjahani, S. Shahrabi, N. Saki

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Twist proteins are members of basic helix-loop-helix family and are major regulators of embryogenesis. In adult humans, Twist proteins are mainly expressed in precursor cells, including myogenic, osteoblastic, chondroblastic and myelomonocytic lineages, maintaining their undifferentiated state. In addition, they play important roles in lymphocyte function and maturation. Recently, several studies have reported regulatory roles for Twist in the function and development of hematopoietic cells as well as in survival and development of numerous hematological malignancies. It is activated by numerous signal transduction pathways, including Akt, nuclear factor κB, Wnt, signal transducer and activator of transcription 3, mitogen-activated protein kinase and Ras signaling. Activated Twist has an anti-apoptotic role and protects cancer cells from apoptotic cell death. In addition, overexpression of Twist promotes the process of epithelial-mesenchymal transition, which has an essential role in cancer metastasis. Hereby, we review the aberrant expression of Twist in hematopoietic malignancies such as leukemias, lymphomas and myelodysplastic syndrome, which is related with poor prognosis and drug resistance in these disorders. Inactivation of Twist by small RNAs technology or chemotherapeutic inhibitors targeting Twist and upstream or downstream molecules of Twist signaling pathways may be helpful in management of disease to improve treatment strategies in malignancies.

Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu H-H, Montagna MK, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013;32(1):39–49.PubMedCentralPubMedCrossRef

Kress W, Schropp C, Lieb G, Petersen B, Büsse-Ratzka M, Kunz J, et al. Saethre-Chotzen syndrome caused by TWIST1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. Eur J Hum Genet. 2006;14(1):39–48.PubMed

Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X. Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007;120(9):1891–8.PubMedCrossRef

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.PubMedCrossRef

Niitsu N, Okamoto M, Aoki S, Okumura H, Yoshino T, Miura I, et al. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol. 2006;85(6):374–80.PubMedCrossRef

Khan MA. Chen H-c, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumor Biol. 2013;34(5):2497–506.CrossRef

Cheng GZ, Zhang W, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008;283(21):14665–73.PubMedCentralPubMedCrossRef

Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003;63(8):1906–13.PubMed

Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–51.PubMedCentralPubMedCrossRef

10.

Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95(10):3208–13.PubMed

11.

Hosokawa K, Arai F, Yoshihara H, Iwasaki H, Nakamura Y, Gomei Y, et al. Knockdown of N-cadherin suppresses the long-term engraftment of hematopoietic stem cells. Blood. 2010;116(4):554–63.PubMedCrossRef

12.

Hosokawa K, Arai F, Yoshihara H, Iwasaki H, Hembree M, Yin T, et al. Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. Cell Stem Cell. 2010;6(3):194–8.PubMedCrossRef

13.

Yuen H-F, Kwok W-K, Chan K-K, Chua C-W, Chan Y-P, Chu Y-Y, et al. TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis. 2008;29(8):1509–18.PubMedCrossRef

14.

Bastid J, Ciancia C, Puisieux A, Ansieau S. Role of TWIST proteins in cancer progression. Atlas; 2009.

15.

Pang K, Ryan JF, Mullikin JC, Baxevanis AD, Martindale MQ. Genomic insights into Wnt signaling in an early diverging metazoan, the ctenophore Mnemiopsis leidyi. EvoDevo. 2010;1(1):10.PubMedCentralPubMedCrossRef

16.

Zhu D-Y, Guo Q-S, Li Y-L, Cui B, Guo J, Liu J-X, et al. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression. World J gastroenterol: WJG. 2014;20(48):18306.PubMedCentralPubMedCrossRef

17.

Merindol N, Riquet A, Szablewski V, Eliaou J, Puisieux A, Bonnefoy N. The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J. 2014;4(4):e206.PubMedCentralPubMedCrossRef

18.

Barker N. The canonical Wnt/β-catenin signalling pathway. Wnt Signaling: Springer; 2008. p. 5–15.

19.

Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011;43(10):964–8.PubMedCentralPubMedCrossRef

20.

Schugar R, Robbins P, Deasy B. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 2008;15(2):126–35.PubMedCrossRef

21.

Ansieau S, Bastid J, Doreau A, Morel A-P, Bouchet BP, Thomas C, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008;14(1):79–89.PubMedCrossRef

22.

Franco HL, Casasnovas J, Rodríguez-Medina JR, Cadilla CL. Redundant or separate entities? roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res. 2011;39(4):1177–86.PubMedCentralPubMedCrossRef

23.

Shahrabi S, Azizidoost S, Shahjahani M, Rahim F, Ahmadzadeh A, Saki N. New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia. Tumor Biol. 2014;35(11):10627–33.CrossRef

24.

Chotinantakul K, Leeanansaksiri W. Hematopoietic stem cell development, niches, and signaling pathways. Bone marrow research. 2012;2012.

25.

Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116(5):1195.PubMedCentralPubMedCrossRef

26.

Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006;76:103–27.PubMedCrossRef

27.

Wu JY, Scadden DT, Kronenberg HM. Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Miner Res. 2009;24(5):759–64.PubMedCentralPubMedCrossRef

28.

Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F. Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene. 1997;187(1):83–92.PubMedCrossRef

29.

Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, et al. Deregulation of TWIST-1 in the CD34 + compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2011;117(5):1673–6.PubMedCrossRef

30.

Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee S-H, et al. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008;6(12):e316.PubMedCentralPubMedCrossRef

31.

Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, et al. TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells. 2009;27(10):2457–68.PubMedCrossRef

32.

Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 2006;66(4):2195–201.PubMedCrossRef

33.

Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem. 2004;279(41):42709–18.PubMedCrossRef

34.

Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101(4):1220–35.PubMedCrossRef

35.

Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, et al. A twist code determines the onset of osteoblast differentiation. Dev Cell. 2004;6(3):423–35.PubMedCrossRef

36.

Haupt S, Alsheich-Bartok O, Haupt Y. Clues from worms: a Slug at Puma promotes the survival of blood progenitors. Cell Death Differ. 2006;13(6):913–5.PubMedCrossRef

37.

Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell Journal (Yakhteh). 2011;13(3):131.PubMedCentral

38.

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6.PubMedCrossRef

39.

Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU. 1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573–7.PubMedCrossRef

40.

Pevny L, Simon MC, Robertson E, Klein WH, Tsai S-F, D’Agati V, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. 1991.

41.

Hendriks RW, Nawijn MC, Engel JD, van Doorninck H, Grosveld F, Karis A. Expression of the transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with stages of cellular proliferation in the thymus. Eur J Immunol. 1999;29(6):1912–8.PubMedCrossRef

42.

Dong CY, Liu XY, Wang N, Wang LN, Yang BX, Ren Q, et al. Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells. 2014;32(12):3173–82.PubMedCrossRef

43.

Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity. 2004;21(6):853–63.PubMedCrossRef

44.

Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem. 2008;283(44):30045–56.PubMedCentralPubMedCrossRef

45.

Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685–97.PubMedCrossRef

46.

Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149–61.PubMedCrossRef

47.

Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101(11):4333–41.PubMedCrossRef

48.

Cortez M, Carmo LS, Rogero MM, Borelli P, Fock RA. A high-fat diet increases IL-1, IL-6, and TNF-α production by increasing NF-κB and attenuating PPAR-γ expression in bone marrow mesenchymal stem cells. Inflammation. 2013;36(2):379–86.PubMedCrossRef

49.

Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med. 2008;205(8):1889–901.PubMedCentralPubMedCrossRef

50.

Pham D, Walline CC, Hollister K, Dent AL, Blum JS, Firulli AB, et al. The transcription factor Twist1 limits T helper 17 and T follicular helper cell development by repressing the gene encoding the interleukin-6 receptor α chain. J Biol Chem. 2013;288(38):27423–33.PubMedCentralPubMedCrossRef

51.

Koh HS, Lee C, Lee KS, Park EJ, Seong RH, Hong S, et al. Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells. Mol Cells. 2009;28(6):553–8.PubMedCrossRef

52.

Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 2001;29(22):4598–606.PubMedCentralPubMedCrossRef

53.

Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–56.PubMedCentralPubMedCrossRef

54.

Campisi J. Aging, tumor suppression and cancer: high wire-act! Mech Ageing Dev. 2005;126(1):51–8.PubMedCrossRef

55.

Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685.PubMedCentralPubMedCrossRef

56.

Wickremasinghe R, Prentice A, Steele A. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 2011;25(9):1400–7.PubMedCrossRef

57.

Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene. 2008;27(42):5543–53.PubMedCrossRef

58.

Rossi D, Ciardullo C, Spina V, Gaidano G. Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol Lett. 2013;155(1):51–5.PubMedCrossRef

59.

Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13(17):2207–17.PubMedCentralPubMedCrossRef

60.

Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci. 1988;85(5):1629–33.PubMedCentralPubMedCrossRef

61.

Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas A-C, Combaret V, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004;6(6):625–30.PubMedCrossRef

62.

Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 2003;25(7):691–8.PubMedCrossRef

63.

Hanzawa K, Momose S, Higashi M, Tokuhira M, Watanabe R, Kajino K, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk lymphoma. 2010;51(11):2054–62.PubMedCrossRef

64.

Kuwano M, Oda Y, Izumi H, Yang S-J, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3(11):1485–92.PubMed

65.

Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008;68(1):98–105.PubMedCrossRef

66.

Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002;128(11):621–6.PubMedCrossRef

67.

Shiota M, Song Y, Yokomizo A, Kiyoshima K, Tada Y, Uchino H, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box–binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16(23):5654–63.PubMedCrossRef

68.

Min Y, Eom J, Cheong J, Maeng H, Kim J, Jeung H, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17(5):995–7.PubMedCrossRef

69.

Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci. 2001;98(20):11598–603.PubMedCentralPubMedCrossRef

70.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.PubMedCrossRef

71.

Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, Van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63(9):2172–8.PubMed

72.

Martelli A, Nyåkern M, Tabellini G, Bortul R, Tazzari P, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006;20(6):911–28.PubMedCrossRef

73.

Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, et al. Targeting PI3 K/AKT/mTOR network for treatment of leukemia. Cellular and Molecular Life Sciences. 2015:1-11.

74.

Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Constitutive activation of PI3 K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3 K activation. Leukemia. 2004;18(8):1438–40.PubMedCrossRef

75.

Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67(5):1979–87.PubMedCrossRef

76.

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European leukemianet. Blood. 2010;115(3):453–74.PubMedCrossRef

77.

Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(1):89–99.PubMedCrossRef

78.

Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res. 2007;67(22):10677–85.PubMedCrossRef

79.

Panju AH, Danesh A, Minden MD, Kelvin DJ, Alibhai SM. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer. 2009;17(5):539–46.PubMedCrossRef

80.

Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885–91.PubMedCrossRef

81.

Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, et al. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children’s Oncology Group report. Blood. 2013;121(7):1083–93.PubMedCentralPubMedCrossRef

82.

Röhrs S, Scherr M, Romani J, Zaborski M, Drexler HG, Quentmeier H. Research CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. 2010.

83.

Venditti A, Poeta GD, Buccisano F, Tamburini A, Cox-Froncillo M, Aronica G, et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998;12(7):1056–63.PubMedCrossRef

84.

Saki N, Abroun S, Soleimani M, Mortazavi Y, Kaviani S, Arefian E. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology. 2014;19(3):141–7.PubMedCrossRef

85.

Li X, Marcondes AM, Gooley TA, Deeg HJ. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood. 2010;116(13):2304–14.PubMedCentralPubMedCrossRef

86.

Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol. 2008;140(4):444–53.PubMedCrossRef

87.

Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35(11):1739–46.PubMedCentralPubMedCrossRef

88.

Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63(4):265–78.PubMedCrossRef

89.

Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004;80(2):140–5.PubMedCrossRef

90.

Azizidoost S, Babashah S, Rahim F, Shahjahani M, Saki N. Bone marrow neoplastic niche in leukemia. Hematology. 2014;19(4):232–8.PubMedCrossRef

91.

Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579–87.PubMedCrossRef

92.

Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648–54.PubMedCentralPubMedCrossRef

93.

Galván JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hädrich M, et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 2014.

94.

Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, et al. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 2012;97(3):371–8.PubMedCentralPubMedCrossRef

95.

San Jose-Eneriz E, Agirre X, Rodríguez-Otero P, Prosper F. Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. Epigenomics. 2013;5(5):525–38.PubMedCrossRef

96.

Shahjahani M, Mohammadiasl J, Noroozi F, Seghatoleslami M, Shahrabi S, Saba F, et al. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol 2015;1–17.

97.

Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592–601.PubMedCentralPubMedCrossRef

98.

Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer genetics. 2013;206(3):49–62.PubMedCrossRef

99.

Rosén A, Murray F, Evaldsson C, Rosenquist R, editors. Antigens in chronic lymphocytic leukemia—implications for cell origin and leukemogenesis. Semin Cancer Biol; 2010; Elsevier.

100.

Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005;23(17):3877–85.PubMedCrossRef

101.

Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46(1):95–106.PubMedCrossRef

102.

Dulmage B, Geskin L. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol. 2013;169(6):1188–97.PubMedCentralPubMedCrossRef

103.

Eriksen K, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15(5):787–93.PubMedCrossRef

104.

Izban KF, Ergin M, Qin J-Z, Martinez RL, Pooley RJ, Saeed S, et al. Constitutive expression of NF-κB is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol. 2000;31(12):1482–90.PubMedCrossRef

105.

Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci. 1994;91(13):6002–6.PubMedCentralPubMedCrossRef

106.

van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res. 2004;64(16):5578–86.PubMedCrossRef

107.

Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med. 1997;185(10):1851–8.PubMedCentralPubMedCrossRef

108.

Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol. 1999;162(2):799–806.PubMed

109.

Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge: CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol. 2000;165(5):2331–4.PubMedCrossRef

110.

Liu TY, Chen CY, Tien HF, Lin CW. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology. 2009;54(2):214–20.PubMedCrossRef

111.

Zhang J, Wang P, Wu F, Li M, Sharon D, Ingham RJ, et al. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012;24(4):852–8.PubMedCrossRef

112.

Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(2):233–7.CrossRef

113.

Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutiérrez-Avignó FJ, et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol. 2011;42(1):103–10.PubMedCrossRef

114.

Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, Bronson RT, et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell. 2002;2(4):279–88.PubMedCrossRef

115.

Mancini M, Petta S, Iacobucci I, Salvestrini V, Barbieri E, Santucci MA. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell Signal. 2010;22(8):1247–53.PubMedCrossRef

116.

Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R, et al. Biological roles and prognostic values of the epithelial–mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology. 2013;62(2):326–33.PubMedCrossRef

117.

Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol. 2009;83(4):313–9.PubMedCrossRef

118.

Rad SMAH, Bavarsad MS, Arefian E, Jaseb K, Shahjahani M, Saki N. The role of microRNAs in stemness of cancer stem cells. Oncol Rev. 2013;7(1):8.CrossRef

119.

Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci. 2010;107(32):14229–34.PubMedCentralPubMedCrossRef

120.

Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20(5):589–99.PubMedCentralPubMedCrossRef

121.

Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ, et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. 2013;98(3):414–9.PubMedCentralPubMedCrossRef

122.

Lee Y-B, Bantounas I, Lee D-Y, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res. 2009;37(1):123–8.PubMedCentralPubMedCrossRef

123.

Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-oncology. 2011;13(10):1090–8.PubMedCentralPubMedCrossRef

124.

Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, et al. Restoration of miR-214 expression reduces growth of myeloma cells through a positive regulation of P53 and inhibition of DNA replication. Haematologica 2012.070011.

125.

Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012;279(13):2393–8.PubMedCrossRef

126.

Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451(7182):1125–9.PubMedCrossRef

127.

Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T. Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res. 2010;34(5):672–6.PubMedCrossRef

128.

Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell. 2005;123(5):819–31.PubMedCrossRef

129.

Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011;9(7):824–33.PubMedCrossRef

130.

Eyholzer M, Schmid S, Wilkens L, Mueller B, Pabst T. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer. 2010;103(2):275–84.PubMedCentralPubMedCrossRef

131.

Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331–41.PubMedCentralPubMedCrossRef

132.

Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013;319(8):1094–101.PubMedCrossRef

133.

Park S-Y, Lee JH, Ha M, Nam J-W, Kim VN. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol. 2009;16(1):23–9.PubMedCrossRef

134.

Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73.PubMedCrossRef

135.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2007;129(4):43–55.

Titel: Twist as a new prognostic marker in hematological malignancies
verfasst von: F. Norozi
A. Ahmadzadeh
M. Shahjahani
S. Shahrabi
N. Saki
Publikationsdatum: 01.02.2016
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 2/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1357-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Twist as a new prognostic marker in hematological malignancies

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer

A cross-sectional assessment of quality of life of colorectal cancer patients in Saudi Arabia

Epstein–Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma

VEGFR2 inhibition by RNA interference affects cell proliferation, migration, invasion, and response to radiation in Calu-1 cells

Expression and clinical significance of cortactin protein in ovarian neoplasms

Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie